阿德木單抗
外觀
單克隆抗體 | |
---|---|
種類 | 完整抗體 |
目標 | EpCAM |
臨床資料 | |
ATC碼 |
|
識別資訊 | |
CAS號 | 503605-66-1 ![]() |
ChemSpider |
|
UNII | |
化學資訊 | |
化學式 | C6552H10080N1740O2052S46 |
摩爾質量 | 147,533.60 g·mol−1 |
阿德木單抗(INN:Adecatumumab;開發代號:MT201)是一種重組人IgG1單克隆抗體,用於靶向腫瘤細胞。它與上皮細胞黏附分子 (EpCAM - CD326) 結合,旨在觸發抗體依賴性細胞毒性。它是由Micromet Inc開發的,該公司被安進收購。[1]
阿德木單抗已用於治療結直腸癌、前列腺癌[2]和乳腺癌[3]的臨床研究。II期研究結果於2010年發表。[4]
參考資料
[編輯]- ^ Adecatumumab - Amgen/Merck Serono. Adis Insight. Springer Nature Switzerland AG. [2024-01-22]. (原始內容存檔於2017-11-03).
- ^ Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. European Journal of Cancer. October 2006, 42 (15): 2530–8. PMID 16930989. doi:10.1016/j.ejca.2006.05.029.
- ^ Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. British Journal of Cancer. January 2005, 92 (2): 342–9. PMC 2361858
. PMID 15655555. doi:10.1038/sj.bjc.6602310.
- ^ Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology. February 2010, 21 (2): 275–82. PMID 19633042. doi:10.1093/annonc/mdp314
.
|